Weekly Stock Review: Huahai Pharmaceuticals (600521) Subsidiary Obtains Drug Registration and FDA Approval

NightAirdropper · 2026-03-15T12:58:14+00:00

As of March 13, 2026, Huahai Pharmaceutical's stock price experienced a slight decline. This week, attention is on its subsidiary Changxing Pharmaceutical obtaining the registration certificate for magnesium sodium potassium sulfate medication and the approval of gabapentin capsules by the FDA, which will help expand the market and improve competitiveness.

NightAirdropper

2026-03-15 12:58:14

Abstract generation in progress

As of the close on March 13, 2026, Huahai Pharmaceutical (600521) closed at 15.83 yuan, down 1.0% from last week’s 15.99 yuan. This week, Huahai Pharmaceutical reached a intraday high of 16.16 yuan on March 10. The lowest intraday price was 15.58 yuan on March 9. Huahai Pharmaceutical’s current total market value is 23.702 billion yuan, ranking 16th out of 150 in the chemical pharmaceutical sector, and 909th out of 5,190 in the A-share market.

This Week’s Highlights

Summary from company announcements: Subsidiary Changxing Pharmaceutical received the drug registration certificate for magnesium sulfate sodium potassium oral concentrated solution.
Summary from company announcements: Gabapentin capsules approved by the U.S. FDA, expanding the U.S. market.

Company Announcements Summary

Zhejiang Huahai Pharmaceutical Co., Ltd.'s subsidiary Changxing Pharmaceutical recently received the drug registration certificate approved by the National Medical Products Administration for magnesium sulfate sodium potassium oral concentrated solution. This medication is used for adult bowel cleansing, for preparation before endoscopy, radiological examinations, and surgical procedures, and is not for treating constipation. It is approved for production as a chemical drug category 4, deemed to meet the consistency evaluation standards. The approval helps diversify the company’s product line and enhances the subsidiary’s market competitiveness. To date, approximately 4.63 million yuan has been invested in R&D. Production and sales of the product are subject to policy, market environment, and other factors, and carry uncertainties.

Pulinstone Pharmaceutical Co., Ltd., a subsidiary of Zhejiang Huahai Pharmaceutical, has received FDA approval for its Gabapentin capsules (ANDA No.: 219814). The drug is used for treating postherpetic neuralgia in adults, with strengths of 100mg, 300mg, and 400mg. The original drug was developed by VIATRIS SPECIALTY LLC and launched in the U.S. in 1994. So far, the company has invested about 8.7 million yuan in this project. The approval will help the company expand into the U.S. market, enhancing brand influence and market competitiveness.

The above content is compiled by Securities Star based on publicly available information, generated by AI algorithms (Network Information Code 310104345710301240019), and does not constitute investment advice.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.